The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).
 
Daisuke Takahari
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Nozomu Machida
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - AstraZeneca (Inst); MSD (Inst)
 
Keiko Minashi
Research Funding - Astellas Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yukinori Yamagata
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Asahi Kasei; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; dainippon sumitomo; MSD; Ono Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Masashi Wakabayashi
No Relationships to Disclose
 
Yu Komura
No Relationships to Disclose
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices; Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takeshi Kuwata
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb Japan; Celltrion; MSD; Ono Pharmaceutical
Research Funding - Daiichi Sankyo; Ono Pharmaceutical; Roche
 
Motohiro Kojima
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Bristol-Myers Squibb; Takeda
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)